References
- Druker B J, Guilhot F, O'Brien S G, Gathmann I, Kantarjian H, Gathmann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652
- Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006; 20: 1767–1773
- Griswold I J, MacPartlin M, Bumm T, Goss V L, O'Hare T, Lee K A, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol 2006; 26: 6082–6093
- Mahon F X, Deininger M W, Schultheis B, Chabrol J, Reiffers J, Goldman J M, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070–1079
- Dai Y, Rahmani M, Corey S J, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI–571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227–34239
- Tauchi T, Sumi M, Nakajima A, Sashida G, Shimamoto T, Ohyashiki K. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 2003; 9: 4267–4273
- Fisher R A. The Design of Experiments. Oliver and Boyd, EdinburgScotland 1935
- O'Brien S, Moore J O, Boyd T E, Larratt L M, Skotnicki A, Koziner B, et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 1114–1120
- Bedikian A Y, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006; 24: 4738–4745
- Marcucci G, Moser B, Blum W, Stock W, Wetzler M, Kolitz J E, et al. A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients >60 years old. Proc Am Soc Clin Oncol 2007; 25(360s)
- Dai G, Chan K K, Liu S, Hoyt D, Whitman S, Klisovic M, et al. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res 2005; 11: 2998–3008
- Marcucci G S, Stock W, Dai G F, Klisovic R B, Liu S, Klisovic M I, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005; 234: 3404–3411
- Tolcher A W, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11: 3854–3861
- Hochhaus A, Kantarjian H M, Baccarani M, Lipton J H, Apperley J F, Druker B J, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303–2309
- Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B J, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354: 2542–2551
- Ravandi F, Kantarjian H M, Talpaz M, O'Brien S, Faderl S, Giles F J, et al. Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance. Cancer 2001; 91: 1964–1972
- Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase-II trial. Blood 2007; 109: 5143–5150